Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma

As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladanyi, Marc, Sanchez Vega, Francisco, Zauderer, Marjorie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436227/
https://www.ncbi.nlm.nih.gov/pubmed/30914057
http://dx.doi.org/10.1186/s13073-019-0631-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436227/
https://www.ncbi.nlm.nih.gov/pubmed/30914057
http://dx.doi.org/10.1186/s13073-019-0631-0

Ejemplares similares